418 related articles for article (PubMed ID: 15157693)
1. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia.
Lichtman AH; Shelton CC; Advani T; Cravatt BF
Pain; 2004 Jun; 109(3):319-327. PubMed ID: 15157693
[TBL] [Abstract][Full Text] [Related]
2. A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase.
Carey LM; Slivicki RA; Leishman E; Cornett B; Mackie K; Bradshaw H; Hohmann AG
Mol Pain; 2016; 12():. PubMed ID: 27178246
[TBL] [Abstract][Full Text] [Related]
3. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.
Booker L; Kinsey SG; Abdullah RA; Blankman JL; Long JZ; Ezzili C; Boger DL; Cravatt BF; Lichtman AH
Br J Pharmacol; 2012 Apr; 165(8):2485-96. PubMed ID: 21506952
[TBL] [Abstract][Full Text] [Related]
4. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain.
Malek N; Kostrzewa M; Makuch W; Pajak A; Kucharczyk M; Piscitelli F; Przewlocka B; Di Marzo V; Starowicz K
Pharmacol Res; 2016 Sep; 111():251-263. PubMed ID: 27326920
[TBL] [Abstract][Full Text] [Related]
5. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Desroches J; Charron S; Bouchard JF; Beaulieu P
Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
[TBL] [Abstract][Full Text] [Related]
6. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation.
Schlosburg JE; Kinsey SG; Lichtman AH
AAPS J; 2009 Mar; 11(1):39-44. PubMed ID: 19184452
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo.
Lichtman AH; Hawkins EG; Griffin G; Cravatt BF
J Pharmacol Exp Ther; 2002 Jul; 302(1):73-9. PubMed ID: 12065702
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice.
Nozaki C; Markert A; Zimmer A
Eur Neuropsychopharmacol; 2015 Aug; 25(8):1388-96. PubMed ID: 25910421
[TBL] [Abstract][Full Text] [Related]
9. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.
Moreira FA; Kaiser N; Monory K; Lutz B
Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120
[TBL] [Abstract][Full Text] [Related]
10. Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics.
Maione S; Costa B; Piscitelli F; Morera E; De Chiaro M; Comelli F; Boccella S; Guida F; Verde R; Ortar G; Di Marzo V
Pharmacol Res; 2013 Oct; 76():98-105. PubMed ID: 23911581
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.
Walentiny DM; Vann RE; Wiley JL
Neuropharmacology; 2015 Jun; 93():237-42. PubMed ID: 25698527
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice.
Kinsey SG; Naidu PS; Cravatt BF; Dudley DT; Lichtman AH
Pharmacol Biochem Behav; 2011 Oct; 99(4):718-25. PubMed ID: 21740924
[TBL] [Abstract][Full Text] [Related]
13. Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour.
Maccarrone M; Valverde O; Barbaccia ML; Castañé A; Maldonado R; Ledent C; Parmentier M; Finazzi-Agrò A
Eur J Neurosci; 2002 Apr; 15(7):1178-86. PubMed ID: 11982628
[TBL] [Abstract][Full Text] [Related]
14. A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis.
Malek N; Mrugala M; Makuch W; Kolosowska N; Przewlocka B; Binkowski M; Czaja M; Morera E; Di Marzo V; Starowicz K
Pain; 2015 May; 156(5):890-903. PubMed ID: 25719612
[TBL] [Abstract][Full Text] [Related]
15. Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors.
Wise LE; Shelton CC; Cravatt BF; Martin BR; Lichtman AH
Eur J Pharmacol; 2007 Feb; 557(1):44-8. PubMed ID: 17217945
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.
Karbarz MJ; Luo L; Chang L; Tham CS; Palmer JA; Wilson SJ; Wennerholm ML; Brown SM; Scott BP; Apodaca RL; Keith JM; Wu J; Breitenbucher JG; Chaplan SR; Webb M
Anesth Analg; 2009 Jan; 108(1):316-29. PubMed ID: 19095868
[TBL] [Abstract][Full Text] [Related]
17. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception.
Naidu PS; Booker L; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2009 Apr; 329(1):48-56. PubMed ID: 19118134
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.
Nasirinezhad F; Jergova S; Pearson JP; Sagen J
Neuropharmacology; 2015 Aug; 95():100-9. PubMed ID: 25486617
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of C-fiber nociceptors in mice with sickle cell disease is decreased by local inhibition of anandamide hydrolysis.
Uhelski ML; Gupta K; Simone DA
Pain; 2017 Sep; 158(9):1711-1722. PubMed ID: 28570479
[TBL] [Abstract][Full Text] [Related]
20. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase.
Bisogno T; Melck D; De Petrocellis L; Bobrov MYu ; Gretskaya NM; Bezuglov VV; Sitachitta N; Gerwick WH; Di Marzo V
Biochem Biophys Res Commun; 1998 Jul; 248(3):515-22. PubMed ID: 9703957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
